293 related articles for article (PubMed ID: 24938502)
1. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.
Aguiar P; Monteiro L; Feres A; Gomes I; Melo A
Curr Alzheimer Res; 2014; 11(6):532-7. PubMed ID: 24938502
[TBL] [Abstract][Full Text] [Related]
2. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
4. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
5. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
7. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
8. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
[TBL] [Abstract][Full Text] [Related]
9. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
10. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Grossberg G; Meng X; Olin JT
Am J Alzheimers Dis Other Demen; 2011 Feb; 26(1):65-71. PubMed ID: 21282280
[TBL] [Abstract][Full Text] [Related]
11. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
13. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
14. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
[TBL] [Abstract][Full Text] [Related]
16. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study.
de Silva HA; Pathmeswaran A; Gunatilake SB
Ceylon Med J; 2005 Sep; 50(3):106-9. PubMed ID: 16252573
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE
Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
